Indeed, the observed heterogeneity of MAPK activation in uveal melanoma with GNAQ/11 mutations could explain at least in part this phenomenon and, therefore, it does not allow this mutational status to be an efficient biomarker of MEK inhibitors’ sensitivity [80]. Here, MAP2K7 is linked to uveal melanoma.